<SUBMISSION>
<ACCESSION-NUMBER>0001193125-09-144069
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20090630
<ITEMS>1.01
<ITEMS>2.03
<ITEMS>3.02
<ITEMS>9.01
<FILING-DATE>20090706
<DATE-OF-FILING-DATE-CHANGE>20090706
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>PRO PHARMACEUTICALS INC
<CIK>0001133416
<ASSIGNED-SIC>2834
<IRS-NUMBER>043562325
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31791
<FILM-NUMBER>09929345
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
<PHONE>6175590033
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>Form 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Current Report </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>June&nbsp;30, 2009 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Date of Report </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(Date of earliest event reported) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>PRO-PHARMACEUTICALS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of Registrant as specified in its
charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Nevada</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-32877</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>04-3562325</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>7 Wells Avenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Newton, Massachusetts 02459 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip code) </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(617) 559-0033 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s
telephone number, including area code) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name or former
address, if changed since last report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;1.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In a
Current Report on Form 8-K filed with the Commission on February&nbsp;18, 2009 (the &#147;<U>February 18, 2009 Form 8-K Current Report</U>&#148;), Pro-Pharmaceuticals, Inc., a Nevada corporation (the &#147;<U>Company</U>&#148;), reported, among
other things, that the Company (i)&nbsp;had entered into a Securities Purchase Agreement (the &#147;<U>Purchase Agreement</U>&#148;) and related agreements on February&nbsp;12, 2009 with 10X Fund, L.P., a Delaware limited partnership (the
&#147;<U>Purchaser</U>&#148;) and (ii)&nbsp;had completed an initial closing under the Purchase Agreement. The February&nbsp;18, 2009 Form 8-K Current Report also reported that under the Purchase Agreement the Company agreed to issue and sell to the
Purchaser, and the Purchaser agreed to purchase, at one or more subsequent closings: (i)&nbsp;up to 2,100,000 shares of Series B-2 Preferred Stock (the &#147;<U>Series B-2 Preferred Stock</U>&#148;) convertible into up to 8,400,000 shares of the
Company&#146;s common stock, par value $0.001 per share (the &#147;<U>Common Stock</U>&#148;); (ii)&nbsp;Class&nbsp;A-1 Warrants exercisable to purchase up to 4,200,000 shares of Common Stock (the &#147;<U>Class A-1 Warrants</U>&#148;);
(iii)&nbsp;Class&nbsp;A-2 Warrants exercisable to purchase up to 4,200,000 shares of Common Stock (the &#147;<U>Class A-2 Warrants</U>&#148;); and (iv)&nbsp;Class B Warrants exercisable to purchase up to 16,800,000 shares of Common Stock (the
<U>Class B Warrants</U>&#148;) for an aggregate purchase price of $4.2 million (less the origination fees and expenses described below). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">In a subsequent closing on June&nbsp;30, 2009, pursuant to the Purchase Agreement, the Company issued and sold an aggregate of (i)&nbsp;250,000 shares of Series B-2 Preferred Stock convertible into 1,000,000 shares of Common Stock,
(ii)&nbsp;Class&nbsp;A-1 Warrants exercisable to purchase 500,000 shares of Common Stock, (iii)&nbsp;Class&nbsp;A-2 Warrants exercisable to purchase 500,000 shares of Common Stock, and (iv)&nbsp;Class B Warrants exercisable to purchase 2,000,000
shares of Common Stock for gross proceeds of $500,000. Net proceeds of these sales were approximately $472,500 after reimbursement of the Purchaser&#146;s expenses (including legal expenses) in connection with the subsequent closings and an
origination fee in the amount of three percent of the gross proceeds from the sale of these securities. As a result of the closing held on May&nbsp;13, 2009, under the terms of the Purchase Agreement, the final purchase date for the remaining shares
of Series B-2 Preferred Stock, Series A-1 Warrants, Series A-2 Warrants and Series B Warrants has been extended to August&nbsp;11, 2009. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">The terms and conditions of the Purchase Agreement, the Certificate of Designation of Preferences, Rights and Limitations for the Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock that established the Series
B-2 Preferred Stock, the Series A-1 Warrants, the Series A-2 Warrants and the Series B Warrants were disclosed in the February&nbsp;18, 2009 Form 8-K Current Report including the exhibits thereto. The description of the Class&nbsp;A-1 Warrants, the
Class&nbsp;A-2 Warrants and the Class B Warrants issued by the Company in the subsequent closings reported in this report is not complete and is qualified in its entirety by reference to the full text of the Form of Class&nbsp;A-1 Warrants, the Form
of Class&nbsp;A-2 Warrants and the Form of Class B Warrants, copies of which are filed as Exhibit 4.1, Exhibit 4.2 and Exhibit 4.3, respectively, in the February&nbsp;18, 2009 Form 8-K Current Report and incorporated herein by reference. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;2.03</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Creation of Direct Financial Obligation or an Obligation under an Off-Balance Arrangement of Registrant. </B></FONT></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The information contained in Item&nbsp;1.01 of the February&nbsp;18, 2009 Form 8-K Current Report under the caption &#147;Securities Purchase Agreement -
Terms of the Series B Preferred Stock - Redemption&#148; is incorporated by reference into this Item&nbsp;2.03. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;3.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Unregistered Sales of Equity Securities. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The
information contained in Item&nbsp;1.01 of this report is incorporated by reference into this Item&nbsp;3.02. The Series B-2 Convertible Stock and warrants sold at the subsequent closing on June&nbsp;30, 2009, under the Purchase Agreement were
issued in reliance on the exemption from registration under Section&nbsp;4(2) of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), and Rule 506 of Regulation D promulgated thereunder. The Series B-2 Preferred Stock and
warrants were not registered under the Securities Act and are &#147;restricted securities&#148; as such term is defined in Rule 144 under the Securities Act. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Financial Statements of Businesses Acquired. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Not applicable. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pro Forma Financial Information. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Not
applicable. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Shell Company Transactions </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Not
applicable. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Exhibits. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>Exhibit Number </U></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Class A-1 Common Stock Purchase Warrant*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Class A-2 Common Stock Purchase Warrant*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Class B Common Stock Purchase Warrant*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">News release dated July 6, 2009, &#147;Pro-Pharmaceuticals Closes $500,000 Tranche Brings Total to $3.2 Million of $6 Million Private Placement.&#148;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed with the Commission on February&nbsp;18, 2009. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">PRO-PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Anthony D. Squeglia</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Anthony D. Squeglia</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Date: July 6, 2009 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">10.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form of Class&nbsp;A-1 Common Stock Purchase Warrant.*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">10.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form of Class&nbsp;A-2 Common Stock Purchase Warrant.*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">10.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form of Class B Common Stock Purchase Warrant.*</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed with the Commission on February&nbsp;18, 2009. </FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>NEWS RELEASE DATED JULY 6, 2009
<TEXT>
<HTML><HEAD>
<TITLE>News Release dated July 6, 2009</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g20449ex99pg1.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PRO-PHARMACEUTICALS CLOSES $500,000 TRANCHE; </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>BRINGS TOTAL TO $3.2 MILLION OF $6.0 MILLION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PRIVATE PLACEMENT
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Newton, MA (July 6, 2009) Pro-Pharmaceuticals, Inc. (OTCBB: PRWP)</B> (the &#147;Company&#148;), today announced that it has closed a $500,000
tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date to $3.2 million. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">At the closing, which occurred on June&nbsp;30, 2009, the Company issued and sold 250,000 shares of Series B-2 preferred stock convertible into 1,000,000 shares of
common stock, a Class&nbsp;A-1 and a Class&nbsp;A-2 warrant each exercisable to purchase 500,000 shares of common stock and a Class B warrant exercisable to purchase 1,000,000 shares of common stock, for a gross purchase price of $500,000.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On February&nbsp;12, 2009, the Company closed a $1.8 tranche of Series B-1 convertible preferred stock and warrants and on May&nbsp;13, 2009 closed a
$900,000 tranche of Series B-2 convertible preferred stock and warrants. At one or more subsequent closings, which the Company expects to occur on or before August&nbsp;11, 2009, the Company has agreed to issue and sell, subject to certain
conditions, up to an additional $2.8 million of Series B-2 preferred stock and warrants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Series B-1 and Series B-2 convertible preferred stock have
the same terms and conditions, other than with respect to redemption rights. Holders of Series B preferred stock will vote with the holders of the Company&#146;s common stock on an as-converted basis. Each share of Series B preferred stock will pay
a 12%&nbsp;per annum dividend, payable quarterly in cash or common stock at the Company&#146;s option. Each share of Series B preferred stock is convertible into four shares of the Company&#146;s common stock at the conversion price of $0.50 per
share at the option of: (i)&nbsp;the holder, at any time and (ii)&nbsp;the Company, at any time after February&nbsp;12, 2010 if the Company&#146;s common stock is quoted at or above $1.50 for 15 consecutive trading days and an effective registration
statement regarding the underlying shares of common stock is in effect (subject to certain monthly volume limits). Upon notice of not less than 30 trading days, the any holder of Series B preferred stock may require that the Company redeem its
shares, in whole or in part, (i)&nbsp;at any time on or after March&nbsp;12, 2010 in the case of Series B-1 preferred stock, and (ii)&nbsp;at any time on or after two years from the date of issuance of such shares of Series B-2 preferred stock. The
redemption price will be equal to the sum of the stated value of the Series B preferred stock, plus all accrued but unpaid dividends thereon, as of the redemption date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Each Class&nbsp;A-1 Warrant, Class&nbsp;A-2 Warrant and Class B Warrant is exercisable at $0.50 per share of Common Stock at any time on or after the date of issuance until the fifth anniversary of the respective
issue date. The Class&nbsp;A-1 and Class&nbsp;A-2 Warrants may be redeemed by the Company upon the occurrence of certain conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;"><FONT FACE="Times New Roman"
SIZE="2">The Company expects to use the proceeds from the financing to complete the submission of a New Drug Application to the U.S. Food and Drug Administration for its lead product candidate, DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, as well as for general corporate purposes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Series B Preferred
Stock, the Class&nbsp;A-1 Warrants, the Class&nbsp;A-2 Warrants and the Class B Warrants, including the common stock underlying the Series B Preferred Stock and warrants, have not been registered under the Securities Act of 1933, as amended, and may
not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:3px;"><FONT FACE="Times New Roman" SIZE="2"><B>About DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;"><FONT FACE="Times New Roman" SIZE="2">DAVANAT<FONT FACE="Times New Roman"
SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the Company&#146;s lead product candidate, is a carbohydrate polymer composed of mannose and galactose.&nbsp;DAVANAT<FONT FACE="Times New Roman"
SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>&#146;s mechanism of action is based on interacting with lectins on the cell surface.&nbsp;DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> targets specific lectin receptors (galectins) that are over-expressed on cancer cells. Current research indicates that galectins affect cell development and play
important roles in cancer, including tumor cell survival, angiogenesis and tumor metastasis.&nbsp;DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is a drug that is
not yet approved for commercial use by the FDA. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Pro-Pharmaceuticals, Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Pro-Pharmaceuticals, OTCBB: PRWP, is engaged in the discovery, development and commercialization of carbohydrate therapeutics for advanced treatment of cancer and fibrosis.&nbsp;Initially, the product pipeline is
focused on increasing the efficacy and decreasing the toxicity of chemotherapy drugs.&nbsp;The Company is headquartered in Newton, Mass.&nbsp;Additional information is available at www.pro-pharmaceuticals.com. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>FORWARD LOOKING STATEMENTS:</B> Any statements in this news release about future expectations, plans and prospects for the company, including without limitation
statements containing the words &#147;believes,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;intends,&#148; and similar expressions, constitute forward-looking statements as defined in the &#147;safe harbor&#148;
provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management&#146;s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to
differ materially from those described in such statements. We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements as a result of various factors
including, but not limited to, the following: uncertainties as to the utility and market for our potential products; uncertainties associated with pre-clinical and clinical trials of our product candidates; and uncertainties as to the results of the
financing. More information about those risks and uncertainties is contained in the Company&#146;s most recent quarterly or annual report and in the Company&#146;s other reports filed with the Securities and Exchange Commission. While the Company
anticipates that subsequent events may cause the Company&#146;s views to change, the Company disclaims any obligation to update such forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Contact: Pro-Pharmaceuticals, Inc., Anthony D. Squeglia: 617.559.0033; squeglia@pro-pharmaceuticals.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">DAVANAT is a registered trademark of
Pro-Pharmaceuticals. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g20449ex99pg1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g20449ex99pg1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`-@%[`P$1``(1`0,1`?_$`+@```$#!0$!`0``````
M```````'"0H!`@4&"`,$"P$!``$%`0$!``````````````4!`P0&"`<""1``
M``8"`@(!`@('!`0/`````0(#!`4&!P@`$1()$R$4,15!42(R%A<*(S,V&&%Q
M4B210M)CH[/35&0E=;4F=C<1``(!`P,#`@0$`P4'`P4```$"`Q$$!0`2!B$Q
M$R('05$R%&%Q%0B!0B.14C,D%O#!8G)#<S2A4[."LF,E-O_:``P#`0`"$0,1
M`#\`G\<::.--'&FCC31QIHXTUS3M;MS@?2W$LUF7/]T:U:L1B*Y(J+0^)Y:[
MI-)HBJUJ])@!7;KSM@D5/$B9`,FW1\P4<+((%.J6:P.`R?),C'C<:@+NU&=C
MMBC6C,SR/0[5559J`%VVE8T=RJ&W+*D*%W[?+XG\!_M^=!J$9FWW2;+[T[+1
MR-6FIO!F#J4UE;!CS'52F56LP,[%N6`1MSNEF8$9O9RRI$6,"*1?C8,DS"5)
M'S.LJKU5[6<%P.)SMK97,27<UR[I,\@J&C:%@T2I7:L98%^WD):C.P5`L#D9
MFN(&#T\8H0.XJ&!!/S((%/@"*@5U)/\`7S[9*SFA.'P_L4]C:=EDA&D;7KJJ
M=-G5\D*^((E3=B($;URUG,`>29A!H[$1,F9(X@B.I>[OL!D>)F7D7$]UUQGJ
MSQ=3-;5/R`/EA`_GZ,G0,&%7U6RS0ILR!53N:CBBHJCZ=Y9OJ/:HZ,>P7MI[
MKG-&MAT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QI
MHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXT
MT<::.-->1%T%#>*:R1S="/B10AC=!^(]%$1Z#OEM9HF.U64M^!&J5&KS&*0H
MF.8I"E#LQC"!2@'ZQ$>@`.70"30=3H2`*GMJPBR*HB":J2@@'8@10IQ`/UB!
M1'H.6EEB<T1E)_`@Z5![:]>7-5U@QM%:"<"L#88,+*9$7(5X99A^>"W!,%1<
M!$_<??BB"1@,)_C\?$>^^N90LKTV?ZB(9?T_?M\NQO'NK3;OIMW5%*5K77TJ
M,P+*"57N1\/S^7<=_GKZY=VI'Q,H_2*4ZK*.>NTRG[\#*-FRJQ"GZ^OB)B!W
MU^CF.J[F"_,TU6)0\BH>Q8#^TZ_*2W2VVSYN)G.Y9&SU?92VR+*QV")JL"*R
MC>IT2NLIA\W85ZGP!#?91+%NB7M0Y2_,Y7.HJH83J&YUMA<998C%PV-C&B1K
M&-S``-(Q]1>0CZGZT!/THJH.BC43E(?MLG<VH8LL-Q)&">]$<H.@Z"H%33XD
MZU_4_P#_`%PG_P!4G_\`KXKF_P#!O_ZZP_[Q_P#C?45<_P#CM^7^\:<S_2`@
M(@("!BF*8Q3%,`]@8ARB!B&*/X"`@(#^'.H>_0]M0A`848`C\>NI77I3V(RQ
MF?%N4:5DRRK6MAAM]0H6E2DD`K3R4+/1]D4/&2DF<3+R:,:$*DFV.J(J)I?L
M"(@`<X`_<OPKCW%<[89'`0+;')).\T:"D?D1XZNJ_P`I<R$N!TKU'<ZV?"32
MR1R+*S-1@14UI44H/D!3H/F3\]/6'<()"(*+))B`=B!U"$$`_6(&,`]<YB:6
M)3M9E#?B1J;J!KUY<U75A3D,)BE.0QB"`'*4P")!$.P`P`/91$/U\^0ZL2%(
M)'?\--5`Y#&,0IRF,3KS*!@$Q.P[#R`![+V'Z^`RDE006'<?+5*C53&*0HF,
M8"E`.Q,80`H!^L1'H`#GU2O;520.IU0IBG*!R&*8I@`Q3%$#%,`_4!`0[`0$
M.45E8;E(*GY::M.LDD(`JJFF)NQ*!SE()NNN^O(0[Z[#AF5%WN0%K2IZ"OR_
M]#_9JA('0]]7$.10H'(8IRCWT8A@,4>A$!Z$!$!Z$.N%96&Y2"OX:KH.<B8`
M)SE(`B!0$Y@*`F,/12AV(=B(_@'*,Z)]9`_,TTJ-5,8I2B8Q@*4H")C&$`*`
M!^(B(_0`#E695&YB`OXZ:`$#`!BB!BF`!`0$!`0$.P$!#Z"`AP""*CMIJACD
M(`"<Q2`)BE`3&`H"8P@4I0$1#]HQAZ`/TCRC,J"K$`?CIJ[GUIJ@B!0$1$``
M`$1$1Z``#ZB(B/T``#E"0!4]`--6D4(H7R3.0Y>Q#R(8#%[#\0[*(AV'**RN
M*H01^'737F9RV*(E,X0*8H]&*95,!*(?B`@)NP'GR9H5-&=01^(U2HU[`("`
M&`0$HAV`@/8"`_4!`?P$!#GW44K\-5U0AR*%`Y#E.0>^C$,!BCT(@/1@$0^@
MAROPK\"*_P`#U!_*FJ`@]1JA%"*!Y)G(<O8AY$,!@[#Z"'8"(=@/X\^0RL-R
MD%?GJNO/[IK_`-Y0_5_?)_\`*Y\>>#^^G]HU2H^8UZ^9/#Y/,OQ^(F\_(/#Q
M`.Q-Y=^/B`?IY<0B2A3J#VIUKJM12OPT%,4Y0,0Q3E$.P,40,40_6`AV`AP"
M"*CJ--4.JFD`"JH1,!'Q`3G*0!-T(^("80`1Z`1Z_P!'*,Z(*N0!^)IIV[ZJ
M0Y%"@8ABG*/X&(8#%'KZ?00$0'Z\JK*PW*05/RTT"<A3%(8Y2F/V!"B8`,?H
M.Q\0$>S=!^/7*%T4A6(#'L*Z:NY]::L*H0XF*0Y#"0>C@4P&$@C^`&`!$2C_
M`*^?*NCU"$$CO0UIIJ_GUIK`0]KJ]A7?-8"R0$XYC#@G)-H>8CI->/4,)BE3
M?(LG"ZC0XF((`"@%'L!_5S,NL=D+)$DO8)H4D%4+HR!A\U+`;A^(KJX\4L8J
MZLH/S!&L_P`P]6]'&FK#*$()2F.0ICB($*8P`)Q`.Q`H"("80#]7/DLJD!B`
M3V_'2NJF.4A1,<Q2%#\3&$"E#_6(B`!PS*@W.0%_'IIVU3Y">'R>9/CZ\O/R
M#P\?U^7?CURI(`J>@I75*BE?AJX!`P`8H@8I@`2F`0$!`0[`0$/H("'`((J.
MH.JZM.HFD`"HH1,!'H!.<I`$>A'H!,(`(]`//EY$CZNP'YFFG;52'(H4#D,4
MY#?@8A@,4?T?0P"(#]>7"".^@(/4=M7<IIK\O3`N0L2N_6M:,E,=LL_POM1@
M]D8MAK=2J+FK)U@N-Y@E'F/4(6&E<>%FI.-4AUWLA*JH.%6X`Z<MDVYBJD.8
MA_V`Y9@+K'^ZMOCH<!B7]GWPC39*XFM+2**TD1KH%X[@QHV_8D!>$,[!7,M%
M45&[9BSB,YMC&WZ>+1RVTD!7W':Y;ZF<>E43=1J_2::G+;ZV/,3?TL[!6?)?
MW],SFGIL]D[K^1RBC"2@;\%48J30LI2'<(J-'B$IYB)D%"^!^P`0ZY^<7`+;
M!'WQQMKA7^YXX<XBPLZT\D!EHI9&'8I3H1V[ZB<9%82<BBBM`7QYFHN_J2M.
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M/QIIJ?)?H0J%+T:LFP<1L!L`\]B]1Q<XS>ZV?<9:L023VZ0E<4M<[46K<\B1
M%K0G2"2K5)(RQE0,4BHG\?[#GLN,_<C<WO/(>#R8S&CV=EOOM!CEME"F-Y=D
M=PV[O<`E6+4'IJM-WJ.?#E;AKMK:%DCM9F*MN6E0215A'N&XBBT`9/2H"J!4
M.H>F/;:\;M>LG$68\I'>R.04H2TX^NE@D5FRKJX3%*46B5K4M]F@U225FVPI
MG5*!"B"OF/Z0YX]^X#V_LO;GW8NL%C3$,7,(;J%$#!8H[CU"*C$GT4(K4@BG
MY"/RD:V]YOMU6.)E5T523L!4$`[NM1_'7YO^5&Z#/*64FC9($6S3)>06S9`G
MD)46[:WS**")/(3&$J:1`*'8B/0?4>>LLJH2J]%'0?@!VUJ,LTMQ*]Q.Q:>1
MBS$]RS$EB:=*DDGII^C3OTX6>63QUF%ON]I*1ED;&L?/1M.5O]C+<8K^,8B)
MGD(J78#7P13E(A'R1>$3.<I%B&\1,4/(<'%\SN>,<J26\PV7E6SN'5O'"#NV
MATJM2.A)J*TZ?CJS<I"+1I9)HDBV@DLU`*D=S_Z:W#9G7&4UDNT12);(V.<F
M.9>`+/A,XSDG\I"LDS.CM2Q[QP_9,CE?B!04\2`8O@(?7OL.=0<%YS#SNTNK
MN''Y#'K;3+'MNT5&DW)OW1A6:JCZ233U?"G74&PAVK);S131-7U1G<*@T(K\
M]/@>@+_#VTO_`*_B7_VJ]\YD_=O_`.9@?^S=_P#W0:G\#],OYK_OTW9MY(Z:
MV#W=[N5'V"["7#$N$X;6K#4EC=NUSW?L5L6U[>8YIPR*M5CZS.-$9&P_E9EE
MT6J;=7Y70@84E3F\3;YQJQY=;_MJXID/;7"VE_RBXR=S'._Z?;W<AA^]O`OE
M:2-BL0;8KR.0$0*-Z*->CN"G'86M5D%\[-1D3<=H:3<*E6`:I3;TW-2BU"D!
MSK^G,O6Q%\T2F'V:YZZW.A1>9[["ZTWS)#QX^O-PPBP=IIP\C,NI59::<M49
M/[A)FJ[$5#H%#Q.<@%$/#_W18KBV)]Q8X<#'!;Y=\?`^1@@!\$-XPJRQT18^
MJ;6;Q,Z[CZMK574=EXDBG3;Y`QB6J.JAD`%%4LI(D](!WU)(H26-26F=#/;C
MK[HEN)[7*OMMD+,CX;IM.W<XT:Q]=R)E>/B(:LK79G,,6:;`LRWJZ(+RK;P0
M*5$BI"!X@()@`>T>ZGL=RKGO#>&Y#V^QUB?%AJ7)$EK:,SR);E&?>8_*:*WJ
MJQ!)K]1K-9G$R2[9;114E/2`>Q@B]70;0*@]*@DDM0U8ZZB]'FTC#;/VC^UK
M+%'N60)_#UL:XKG<;P]S=V9DE$1BB\C'+':4^><>%:4<.&!Q%,J")Q)UV'0\
MTK]P7!WX)[2<(Q&1MK2'D2"\%R\*QEG:L;A7E0?U=@?;7<PJ#M)'76=GK>"/
MCZ2I&%E,MLIZ4-5MW5ORJRDFE-QHQJ>NNT??AE^]CA37_2'"]@GZYFC?S/\`
M3,.1,W5EW#>;KF.XB7BIG(UE;.(]]'R;4\4T6:*]IJI`JW37(*@`(@;2?VVX
MK#Q\BRO/N1I!)@>-8F:Z9)6VHT\BM';HVY&0JY$B[6H2Y3:">FM0L!:J[3W@
M<P(.H4,20>C4(4C<J;G525+%?2>A(\/0/F:]K8+SKI+FZQ3UBSGH5G>Z8;L$
MG:'3AS,SM#=R\C)8_G!7D'CV3>)KL"*@8ZJB@IE.D03?4`Y7]R&"Q@Y!C>?<
M<BMH>,<CQ<-S%'``$CE1%2:,[%6.H.VA3N=U0"#KZO[>0.;E(PEF2%4@A@#M
M#!68,X:3859R#0L2!]).N9/?_9\40NV?JBB=B<EW'&VMMAO&>VN:G]7OURH3
M5Q7$(G&ZC(9J0IC]D_%HA*F2`5/J9)-13Q,0#&'FV?MIL,S>\5YFW&;*TON4
M16%N]JD\,,X$F^0%D28%#*(R_C'4EZ`*Q.TR6+BE?#WDMJBM>(\14T!(%)-^
MVO<[:D+U!8+Z20-?5Z'6UDD-F=XK=KS;=D[AZPIQ+')M8Y_8IW>'0S-S.R<.
M;X;'A\AD1L1Z]$R2R[?S$A#':?:"Y#[DQQ'Z_<A';V/%..X[DMIAK7W;4W!R
M,=@L*&**JFV\R0-L#2Q,K]`06#;**`#;S$=J@62:W>#*RHKT4GQ[=TBLU#V+
M%5**O1`"I'8E.?ZFRW9KLDMIU@37RX6NK7](F:]A7Y*A9IBONGT'BNKLG"!Y
MHL0]CU'$,R=$5./F<Y?D']P>N^27[3<'QU+;.\LY?;6D^$4VMC']Q&KCS7,A
M!2,N"!(R$;:[>WUCIK+X[8P7,,TT[!4CHU6V[/3U&[U!]H8J6H-I%%))--)A
M[$=_+MO9ZVM"L1Z]7J6KN8MR:O.91RQ-5B1FXV8J=$U/J#ZZYL>N75?!K,QR
MO\7UMNH"`B@5=D8PB(H")AFO:OVLQ?`/=/DN5Y3;V\^`X_+';6T<NTI)/DI!
M%8J8Y`Y9#$[`N01')MJ2U`:66/L_U!D5TEMO-"E-K))24H=Z#?1%1F4."S'Q
ML10DZ?:]+V7WV<_5MI7D&5F7-@EAP\RI$I+OG3I[(O)#%4Y-XM='DWKY15Z]
MD@5IH@NNJ<ZBZH&4$QO+R'G3WZX];\7]X>08BT3QVHOVF1=H156Y5;D*B@`+
M&OFVQA0`$"@=-06054OYE5751*U`P"FE30@`GTGNA_F0JQ`)H&//>E:MB=R=
MOCZ8:GWVW4>4THU<O.X.1)2I35I@/S3(0)0<K3:-*NJZJDB\5>5!,KN,27\B
MG=**E\0Z$W.@/V]XWAW!.%1^X//K6VNK;D&8BQMNDRQ3*D"EUEF\;>M/ZU4D
M84;QJI44-=9]HEC:16]W,5-V\C%23Z$V$`"4,40(QJY9F8$1[`I)(U(8]:6U
M++='1O7/8=)9(TS=,>1#>Z-2O"/7$=>J^E^16MH_4(4GQO5)9@=P8@@`E(N7
M\0$!'F;W8X>_!/</*\8V,EM;W;&&J%`T+^N(H"35-K!0P8@[3UJ"-1]ZC+<L
MY1T23UKN`!*OU4T4D4(-10].QH00&3(AE(>X_P!JNY>),@YYS#4-0-`T:/0J
M_A["][LN*_YHY(FG,LUN$Y?[#6W364DHR/G8"7BUVI5$_F;)MOB%,2JG/[S<
MW5O['>S7'LCCL582\\Y2;FXDN[F**[\-K`8UBCC23=&K,LT4J^EMI,PEJ2BI
M+7$?Z=B5BDC*7\S*ZNK`T4!'#-4'NK[?'U2A+,2P4+(!U1U/QIIQC1WB?%$S
MDB8J;FU3ML1')]_G,CSD<ZGUB+N(MA/V%1>4)!LQ3`K9!1104B]]F,(B/.;.
M8<OR7-<M^LY6&SAN_&J$6T$=O&0O9C'&`NX_$@"NH"1VEF>=OJD<M0=`*_!1
M\%'8#X#4)^SYPT/K?M-]I,+[&KOLT_KK+/<@RPM"8MN6?E(Z$#YT_P`^;A&8
MQF$FL8B)#)?"58")%*!@(7Z\[VM^,<_N?9'AUW[58W"OD)+,->RSP8_R,NST
MLSW:U<5J2%JY-">FMD^WO'QZ)81N)7<$N`A%/$BA*,&*DDEJ@`?$FNIJCH*I
M&Z5N#XQ7GFM(;:TJN:`YEW\RI9F]8_EH+BLK24E++GGQFDHPR)E57"@NP6`1
M.;S['G`>R<\P*7_C:Z;)MY=JJ(RYG)?:H`4(6)VJ%"A:``#IK"P\3#D%M#<@
M%_O(PX-""?(`P-/216O;H?ATTV7Z>+'8YST48DLDY8[!-61QA+8IVO8YB<E)
M2P*NF]ZRV5LY4FWSMQ*&7:D1(5(XJ^212%`@@!2@'LGO+:6EO^XR]L8(HDLD
MRUHBQJBB,(%@&P(!M"TZ;:4ITIJ0R,,47)XX451%OM^E.G58ZU^=>YKW))-2
M=:I_3@24WD7U4Q/\<V2T6MY,YEV,@W\Q8+)-3$\I&J7B2CRH$G))\ZE4OMVI
MQ*D)50%(?J7H>9?[I+:TPGO5<+B((+:&*ULG5(XHTC#>)6KXU4(:MU(*T/8@
MC47E`L&3D,:C:LTAH>W^*YI3Y?"G8#H*`#7`.PGK@UTI7N+T'U-K<QL!'X0S
MKAK8V[Y.J_\`F3S2NK8+%CZK2\U5W9)5:XGDHY)H^:E%1-!4A5@^AOI].;YQ
M?W4Y'D?97E7+[ZVPLG(,9?8Z*WE_3+$%%NY@DU5$(1C3Z:KZ36GX9,61N)+6
M:1A'Y`'*G8OIWM&.@IMH@8^/<#M_'4A_+^)JKKEZ[\^XKQ:XL\;6,>:P9^1J
MKJ8MMAL=I8"K1+O.E<*6^:D'EC=/6LB^.9!=1R95$I2%(8`(7KFO'9R_Y/[B
MV.;RWB-]<9*TW^.*.&/TR1(`L42I&HVJ`0JBIJ35B2<:SE-YE[=YE3U31`@*
M`IH54DKVJU*MTH23T`--(#Z.)N:L7JOT_FK%-3%AF7^.#+OYB>E'\S+/5AFI
M0/D=R4DX=/7)P*```G.;H```^@!S9_W`6MI8^[V<MK.*.&UCNZ*D:JB*-J]E
M4`#^`[ZP;M0E[/&OTK,X'Y!C33-.D6O\M[O,Z;@[3;=YQS]"8XQ-GF<P=@_`
M.&<NV;&%.KM:IKB1:K/+$G75$5)&0?>)%#JI'(X75.<3J@F4B7/?_<G/V7L%
MQGCO$>$8W%3Y&\QXO+J\O;.*XFD>0+Z5$FY5`:M.K`(``H8L=360F>T:W:TC
M6.T6I6M&+E6"OOZ^H%E;HZ`;2NRA#$R@=9->:=JG@ZBX!H$_?[/4<?(3C>'G
M<HVYY>[V_)/V>:M;L9ZUR"2+N6,V?SJJ+<3E+\+1-)$/V4PYQ]RGD=WRW/W'
M(KZ&UM[NY*%DMHE@A!2-(ALB7TKN"!FI]3EF/5CJ`=V<@M]0517Y[5"U/S)I
M5C\22?CJ$M[6,\[59WV^VWWGUIR'=(W!7J6R=KSBG^'X.R3\36;[,LK3,N<L
MN7+:)?H0DLG"Y!33CWP*E<&<Q$JU$1*4/`OZ">S7%>"\:X9@?;[F5C`W+>:V
M]],9'CADN+:/Q@6Y5)0)$$EO5XB*+YTDHW2HVBVQUI^GHM]'2:X4['3K7;_4
MV/1R"VPAE)"`!]C48`F<!KYF6K;$8-Q-G.E/4I"K97H%8O,,Z0`Y4CMK!%-G
MYDRE4`#@+9=4Z8]_I(/X\_/?DV"N^,\AO>/7RE;NRNI(6!*DU1BO4J2O4`'H
M3WUK$B".1HPRN%)&Y2"#3X@@D'^!.H]O]/[;[?9]I/=0TL]NM=F:5_<"%CX!
MI8[+-SS6!8#9,[%%E"-I9\\0B&AB()E%-N5,@E2(7KHA`#JW]UN*Q6-X]P23
M&VMM;23X%6D,44<1D;[7'G<Y15+M4DU:IJS'NQ)GLY%'$D!C4#<@)I\_'%_M
M3M4D]R=+U_46DVJ/I%5C:XHY=5I[+-=-EME@P1(N8G*"^$XQ)^M),8>1C5B3
M+2.<3!FRCA1L7HJJ*`N#@T^=-72?VLQ\1E]R'7DWV/Z@<?,N.^[%8!?.42,E
M20K/L+JJM7ZB4'D",MK$16$L%P)V47^U1"'-%.[<K#X>JI0**@]21U%1C?1X
MOZD)IKDNY>NU[;(7*4[7JI#YUH.5+-<5LJ1ZD29>3;/IVOW!P))7QE)A=)>;
MBRKL'+@#)@MV42!E_N.D]\8+FRQONT\,V+229[&2`1&W*[MA$9C]48(0%89=
MKA"&VT()IFERWF,N0=GA9R%I41@CX("`1T[;O45I\*:D%\YAU":.--1MO>?:
M[77-P/2DRKEKM%<96#;2ZL)]G7K'-0;2>8D+B@Q&4VUBGS1"7:$^4X`DX*H0
M`4.'71S`/57[<<;C;_B?/I;^VMYY8,%$T9DC20QL1>5:,NI*-T'5:&H![@4V
M/CT4<DC^10U`Q%>O_0G_`+?GU^(![@$+M_4>V6QU'U.9VG:I8Y^JS32T8F*W
MFJS-2=?EFZ:V0X))PFC)1#IF]3271,)%"@<"G*(@8!`>N1_[1L=CLI[T6MGE
M+>"YLVQU\2DT:2H2+:0@[7#+4'J#2H/4==8N"2*2^*S"L?BD)_@I/^U-,-:/
M[SYMQIZZ/81ZX]LK/::_G*KZ'96V7U7NEDM3\;!<<7Y)P<[R26&K-O>2!)6;
MF*^2Q$EXX6JR[E-`LD3R3+&B4GOON3[=X'D7N7Q?W6X7:POQ5N2V>,R4"0T6
M*>WR`M?)/&`46.7:L!WA5-8.A,P)EKRQLY;N.XL53[9+A(Y*%ZDD@5*E0%`Z
M+NW5=C6@Z%I/_K.R&>N^I?4O*=VE9.9"N:?4B\V>8EY!U)RKY""QZE.2KM[(
MOUG#MTZ40:',910YC"/XCSC/W,Q?G]X,_A<8D46_D=Y!$O1(TK>2(BT`HB+4
M#H**HZ#IK6[Z,K>S10*S,)&"J*DGJ0`!W)/8?$G3(/K0U,5]T-6S+[`=U\_[
M`2I[YER^T#%>',.Y@NV*,98RJ%-*,"P6:0L$\*#N82*NFJU6*H7ZI>;K[DZA
M@+T5[L<TQ_L5E;;VN]O\/C*6=G#/=7-];0WLL\MP!(=LCCHE`0:HO>D>U5!.
M=-<#&WS+!!$%V;2'WL2?I+,I8*'&T]0*BOPIJ4]@G#=7U[Q!C_"M+DK7,5;'
M%>;5N&E;S87=LM\BU;'55%[8K&^*1U+RCE98QU%C%+V(]`4I0``Y(Y1R*_Y;
MG[KD>36!+Z[DWLL,8BB6@"A8XUZ(H50`!\NI)ZZBYY3/*92JJ33HHH.@I^/\
M>M2>ITK/('5K4?3T,>K*R:':^V5KM#AG"R>QZN8+#/UW(T+&56XW!C0W59J[
M*(CF>0#0B-@CFR$HE)"#1-8I"?,8P!_:#SJ;]S/O;8^Y^?MDX9>Y)>)KCHXY
M[=V>*&2X6XGDWM`)#&Y"/$!(R[JK0=%4ZV#-9;[YD>U>187BHZ5(H0[4#`':
M:@*PH2*4J000'._8KA>^;%Z,[2X+Q>S8R&0LJ8=ME,J#*3D$HJ/<SDPT!!DF
M\DEBG29-Q/\`O*"`@4/T#SP_VVS>/XWSW$9_*LRXVSOHI9"HW$(C5-%'<T[#
M4?B[R.PR$5Y*&,<;U(6F[^%2!7^(TPOKOZH=S]$Y#079[52L4(F;JSC%KA'V
M"8!7O:=:I.:JHC)3#UO=F-I;-'D>YO,6@JB5)PJU4`SA!BJ)?%NLBOT?R+WH
MX7[B6W(^#<UGNEXM/D&OL/?+#YY[28E?Z1@=U'A9=ZD(\;!7E4-ZU=,^\RD=
M[YT4B+'$1F./Q)O4AP6V!2J[FJY=F<$@UW-01L]=[/=%XCV-:89)UM?RI*E9
MIM*,MV.+%()@LUK.2*S\KNO*3*;4KP1B7Y'#B-?G0*LHDT>JJ(E.H0@#X7[-
M>Y%S[5\_LN6*)'QZUBNHDINEMI:"116@+(0DR+N0-)$BLZJ6.L'%WHL+KRN"
M8&4JX%*E6^50>QH>E":4J`3IE%Y2OZC/+^MY-"+GB/5?&T#-5)AB&X;DAD*5
MEIIQC!**8PLG)LZTQMDM*NKW*1;58CMT:)0:/`<"DFU9B/W!.@3/^U'CV>3W
M,Q5_E<A>1RO<1X=X`H^YWL\6Z0VZ0I!&Q4A!+,ZLH?<]/&<Z>7#6KK?6/D>=
MA58R!MC;J?ZAD#U`!%`OD(9:ER"-2`=+]1Z%H]JEC#6#':R\K!XVJ0QCZ>>-
MR(/[;8W::CJQV9\U3.JF@O-RJRBA40,<$4A(GY&\?(>6^=\US/N!RJ\Y=FFI
M?74A8*I)6)!TCB0GKMC4!:T%2"U!6FHF[N/NIS+L1`:`!5`%`*"I[LU*59B6
M/Q.ORWL_)$0S_GQNFD5`C7.>8FH-R)@D5M]MDBS("V!$`*"/VXI^'AT'AX]=
M!UUSI'&"<8NT-T'%PUI`S;Z[COB1PQW=3N#!@3]0(;J#76KN5+MMI0,>WYZW
M;5!%$<O%,*2?9JI8/(?C+V/:\4(]CUV/8\WC@W3EUA3_`-X__&^L:Y_P&_+_
M`'Z<U*0I`Z(4I0_44`*'_`'7.HB2>^H74E'T!I*A6MHEQ24!!2QXI336%,X(
MJ*(Q5X%9--40\#J(@J3S`!$2^0=]=ASBC]V[H;_!1@CR"&Z)%14`O!0D=P#0
MT)[T-.QUL6!'IE/PJO\`OTH[?U@%R3[@]G-O-B\(X6RWKO=L+8BKF)TLC0]9
MR`\89"I]=JD1,R04ZQP\BUBSHA&N4TW(B83`!1``'Q$-4NO>P8[V&X_[?\2O
MLK8<NL+ZYDN)+=WMU,;SW$L:B:*57<$3(=NW;N5J_2I;?GR,,>'@M87E%\I)
MJK,J@%Y-RL`0&;I&P-&`!Z,"6&GR(V-CH:/8Q,0P9145&-&["-C(UJ@QCX]B
MT2*@U9,635-)LT:-D2%(FFF4I"%`````.<URRR32--,S/,[%F9B268FI))ZD
MD]23U)ZZA))9)I#+,S/*QJ22223W))ZD_B=,P>J72#/6I6??9ED#,4;6V-;V
M>V+@<D8H5@K"G-.7U98(W4KEQ,-2-6YHAV`SC<`2,)Q$?+Z]%['WGWH]QN.\
M\P'$[+!&?[G$8I[>Y61`E)#X`-I#,&']-C6O8CXD@2>6R$-_*&A5P%"CU`=:
M11(:4)^*'O\`"A_`?+HOHYG_``1[//9=M/D:/K:&*-GGF/EL5OXZQDE)Q\2N
MMS)2(S40#5)2)^,1`">2A_+EGW`]PN.\C]I>(<-QGF_6<,MV+D,@5!Y9`R;&
MW'=4`GL*?'KTU*97.VE]B5Q\*2"5&MS4A0I$4!C:E&)^H].@J.O0]-(EM[ZE
MLP>Q/V4/<TYWRME+`NLF`\15BJZS3^NF1XFHYFE<@2BSJ2N]C6D7T!:VE-09
MOI!XV^9)K]\_9&;%^5$J9T^;=POWKX[[8>T:\7P&.L\MRO*7LDN13(1&:R6%
M:+#&(@(C,618R0TFR*02$"0,I7`MLS%;6`LH[=6D#$L7)*,22*[=W<*%4$;>
ME00>YQNG'J7S=Z[O9RZS+A+)>1\Z:KYWPY)5O/\`;=@LEP=PS@AD2/>!(5N5
M>2+>I5HMH8@]:-P(J5,KM%N94AU5"^*8TY_[WX#W*]FX>+Y3'6N,Y7C<DLEI
M#8PM#8^!QM?9%Y6$3JI?<#O#G;M5#5M?$^5M[BR-HULJ2[MRLAVH#7J2G]Y@
M2"U36B_PZ/\`9=Z_;ANIMMZ[+4[HE0O^O.&)[.K?8R$M<L@T!W3LEU2LUQJQ
MCHHQ/NY5=U]JX$3(*(JMOC!0BA5`)S3_`&K]RK3V_P"(\FABGG@Y/?16?V+1
M(&VS07`EWL6.T*E`34-N[;6!(U:M\C]MB[FRC,J7,[Q%60[:!"V\%@P8;E-!
MM!KU!(&L!ZM=1=T_7SE3..KEJF&67O7V29?VG4V^R]V*[R5BE@^<E>'QC/UM
MXS3,Z@OMGWQ@JT41;HR+)=PD@5)^"+60]X.=<$]S\)C>80)+9^Z0C2')0I`H
MMKHJ&!NUE#@J]0/0R.2DBIN'@W2YF:O[._2&:(?YLQ@N0I%#V*$ES4*16,T8
ME&`9QM"*H.3]-,SY:]P>)=JK)`U976/$FH.3L+I+.)PAK%/VW*KIR289#7B(
M**#%I1CU5)18ZB78&#Q`W7UAL5S;CN(]D;WAT$MT>87N=M[Q1XD,,26P78WD
M+@A]ZA@/'("W0[1UU&,8DLT"2$W#%ZJ%(V`E*#?N'J)3<"%(`-.AZC@'U7>E
M?+6FVZ>RF1,LJU>>U_@:QD_'VGL6UFB2+B#J^7K,TEK`X<0Y6+=6%=H59J$,
MN914YW!!-_Q`)UZA[R_N"QON'[=8C`8XW"<@EDAERQ,859FMTVQH7#G='Y#Y
MTB5!&C^I=A+*TA>96WO,?';*DD=Q&44GTT9$4@`L-I:C'TAQTH#4M4EPSTI:
MBYWT9TT>ZWYX;0R,C2\UY4>8]/`SR,^R?8RL<BQGX%\*Q$&YX]V[E7[\56RO
MFHF?LPF$#!UYS^X?G7&O<7W!_P!4\7,S6DMA`DAD!#>:,,C4!``&T)3:JJQJ
MVU22!BY2]BOIUDA#;%C5:LBH[;?YI"C,KL?[P"4%$"T0,S9>%/0_EC87,6VF
MU.\6PFS.NF9\[YGLSRNU_3G8*#J\,KA=1-'^'*_<I!_C>Q/9,S`ZBR+=H5P#
M5!H4A13%03F'U/D/[C..<=P.$X9[?X;$97`XRRC+MEK%IBMY4EY+<BY%*]&+
ME$;R%MOI"G68,VB6:6D,$?@*+O210:E:_44*K)U+-N**:L?36I/='ILT5V(]
M<[K;/7.[OAMNLSO,!\A:PWF0LT3*VQ]$S;,J%I3NL5'QL89G8)19)JLJJ1,J
M)U6ZI@*4#E#GG_OY[D\6]UFPO*<9%X.6"Q\600(ZIO4@IXRTC@HA,@6@#%64
ML21TQLC?17\:-'''"(R5V@>HA@&+5"T*AMP%2"H*@*15M<O99T@]D^D7L(SU
MNSZW*UAK/6--LFD/*YOP!E*>6IDLQLT`+-,QJK.'DXMG]V_75=/63]5X*;=1
MZ[17:*$!`P[;A>=^TON1[:X?V^]UKK(XK.8-I4M<A%&L\9AE-:3(J-+L`"(8
MXTJ?%$XDZLHK%<6]W;K%DY)`T1V1E3N-)`/5(K#JD)1?I<,5?:B>FH>?THN&
MZEWQ=,SN\V*L0X=R>M<I,*S3</V:6M<8UH)F<<K#FLLI)OI%%2UI/E'*+D6B
MOVJA$B*$*GYB0O@?N!9<!Q^=^S]N[N^OL(D0#3W*)&9):G<8D55814VT\BAZ
MUKTIK!G^T-#:>7:=U1(%!'J.T>DL#1-NXUZM4@`4`9$QWK'[7M.]^?8=L3KU
MKC@#,^/MMLKC:ZT>_P"<WM(?Q\/''%2-=*QT;79(X.'15U"G24,44Q#Z&$/Q
MZ$R/,?9CG'M9Q?B')\GE<?E\);;)##:+,C%EHR@M(AZ$`A@2".FVO76;-?P3
M8Y;'^JCI)OJ$5P?Z:)3_`!4(ZK6O7\M2*XZ'LV2<+-(#+40TJ%OO6.$XC(D'
M5)8)5E6YVQ5[[.SQU>FWK(2R#>+>NUDVSE5N(*`0IS$'L0YRH\MOC\P\V,8R
MVD%TQA9UVEXTD/B9U!])=`I90WI)(!Z5UAVER]E=QWD-"\4BNNX="5((J`?C
M3J`WX!OCJ,Q@K"'O$T8U>L/KKQ/K7KIL!CML.1:MB/9^2S(C68NIT+)<O97R
MIKCCY\WB+/(S40K8%G0$;$62:G5!$!?)I^1NPLKG/V[^X'+T]X.09G(8S)J8
MIKK$+:.\MQ<0)%3[>Y7?"D4CI0^1D9Q4U@)!U.";'7%\,C)<;'C8-M,<@:1E
M&ZNXRSA`7HJJ/2B`)0T\A>J]5^D3[U\:5XQUMG;,QN%QAW=FN%^L$21RG"O;
MQ>IIS8K$G!D=E2<_DS)VZ^!L8Z:)E$TP.9,AC"'.?_>;W#@]T?<&\Y?:6YM;
M&41QQ1GZQ%"@1#)ZG`D8#<X5BH)HI(&H?(7*W=Y).@HC,2.E#U)))&YZ$DDF
MC$=>G3219YU`S1?_`&\:([AUV/@%<*8$PSL/2\B2+J<3;3[2=R+5)6(K*49!
M"W.K)(+O7I`54!0H)%[$?P`!R>-<QPN,]G.4<*NFD&<RM]C9;<!:H4M9@\NY
MJ^DA1Z10U--6HIUCADA(-77H>E!ZD/7K7LI[`_#^#@.R]*G\E:X[`8YJC=%W
M:;_A+*M*K35RX39MW,_:J)/04.W<.U?[)JBM(OTRG4-^R0HB(_0.>>\<O(,=
MR&PR%T2MK!>P2.:5HJ2JS&@ZF@!Z:K93I;7D-S("4CE5B!WHK`FE2!7ITJ1^
M>N9_5AKSDK5/0C7+7_+[*+CLC8UIAH.T,X:42F8Q%]^:/W(`SDT4TDW20HKE
M'R`H?4>NN;;[O<GQ?-/<;+<EPWD.+N[DM&77:Q6@%2M32M.G6M.X!Z:MSR":
MYEG4$+)(S`'N`QK0_"OY$Z9-Q=IK[:/4WL1L,MHMBW$6Y>K>S&0)/*8U"[7Q
M+'-LQG97KY^Z,V.XG;#&MTCE3DS(&7:#(I/T4R'42;JD#OI'(<Y]D_?/C&-B
M]R;^XXQRS#6RVZR1Q2W,-S'L4>@1QRL/4N\K)L*DD*[*>FP1MA+ZW;[PB"\`
M6C@-5F(]0*@/5%/4>L,2QH%%07^:-9]RY'360M.2,<8K@]UE\=9&?,,9TVR/
MU<5M<BD7LX8NA#VB85DWH1JS(D1^;.A%8I5SN3)$\`(3G+>3M."ISK[+%W5^
M_M]]Y"IN'1!=&V/C%Q((P-F\5E,2D=0$W`$D:@KN*&&Y>*"426X;TN%/TGJ/
M2VPL5KM/T!B"1M!%([>JW],\K(:O2L1M7MOMY0<VY;?7.S9@QM@?.->8X`DK
M#,RC@(1Q9JO)XWEE+S(*Q+&./*KKN0%PJD*:0ID33,'4_-?W916O.(\EP;!X
M"]P^/BA2RNKVRD&0C01#RQI<"XK$!(\R(46FQJLK%F!G&Y`%N4FA@1D0*`TE
M3+0"AK)O<D]QN)8GN>M1IV+TH:X[::@:@#K+M;'P!7.*+]9X[$$]!6QM:"S.
M*95X>4A6SLC=DR"'4A'*ZJ)$#`813,`]_H#Q3W]Y1P?F_-_]7\),BB^MT:[B
M:$1!+E1M8A@S>7R*`S.54UZ=>^HS(W=K>2":W1T?J&!"`4#'9M"_)-H8MU)%
M=-I:BZK>W/0'8??:\X=UDUWS!3=MMAG>3(R0NV?'E2D(6O1=CR`ZA?&-BZO(
M^;F4CKH"BI%%`%`Z/C^UY"(>R>Y'/?9#W7P''+7+Y7+X^]PN)CMV6.R24/)X
M+:-_49UH%>`[2*[@P)H>FLO+7MG=F..-Y`(D45$88,3'&#3=+&1M*D&J]3VZ
M4)?GW%R+N-C?#%>M6GV!*-G_`#$>WUYG:<9W"]H46,2ICR!GE+!*0EF>NH]F
M>5B;&E')IIK#XK-55A`OF!>N:/;G#\%SF=>P]PLI-A\.;5RES'$TX$X>/:KQ
MHCN49/)U4`APE32M8NV@BN)"DTRP(!7<49Z]AM`4@@]:U/3H1\1IIWUUZ!;7
M.O8CFOVB;@8PPYK-<,AXX)C2IZ]88EFED`?NS1@6"[Y%GV*2T0^LTF2'1,=P
MT<J'>KJ'45!/HI!]E]T_<CB-M[96'LOP3)9#,XFRNQ,][<*T43(JD0PVT3L)
M%BAW,%22-`G_`$Q1B=2]S<V5MCGQMO+)<,[1-O;HB;%H1&I&Y5)/T=E(+;WW
M47J_+^Z^R=6]NFM.DF.J50+G@N_8/NF4<SOV8.WF2*`UC%7L;#VB7?(SR4;4
MZ\,T1HBV3=QZIY<RJB2!P4\1+HN&]ON,WOLKE?<3)7-];<@M<C%;6JL@%I<%
MMK/&C&,M+*(]Y8I*HA.TNK`T.!]G&,;]]OK*7VA:;0*,@^H]')5F:B=5"U.G
M>>>+ZC],I^U/2#/.V.QGK$R3A^-K;ZKZN;"V?(F65YVPIPKMC6I0E!^T6AFA
MVK@TPZ-_#KD!2*)!`0+]>C=A[W[,^XO'>"<<Y=89SS_=9C%1V]L(T#UD'W`.
MXEE"@>536O;=05`!E\3D8<>[&97(8,/2`:5BD05J1\7':O2I_`JE[J-3<Q;M
M^OC+.NV!X^$E,EV^<Q\]AF=BFDJ_%';UZXQ4S)F7E%D7!$3)L6AQ('B/F;H/
MIWS%_;QS[C_MK[FV_*>3&88E+2ZB)B3>P::!XT].Y?3N(W$&H'4`]M6L7<Q6
ML[S2GH()`!\68H0%'PJ3TZT'S(TV%[4?2/E#;_2O3(^&VM5@]T=9\+XKPQ:#
MN;`:%A[QC]/'D54;[3'%G;MR@X3@ITBCMBLN0R2K$[YN"?\`OG9?5_9K]Q.+
MX%[@Y\YMKF7V^S&0N;J-0"[03&9I(I5B+;5,B428+1BRPL6(B`UF6>:2VN)&
MEB,MG)+OH>K*0=RD*3LKNVDGN"H(;I0O;Z,ZZS^(O7]KKJ]FZ(B74]3]=JGB
M3)L$PD#24*Z60J*5<LT6A)-RM3NV+E(ZJ7RD`@F(;L.N<V\ZY%#F?<;,<LP;
MNMO=9FZN[=V4!@LEP\L3%6W+N`*DJ0PKT((U%S73->M>0U5C*76M*@[MPKW%
M1_$:83UTU,]SGJ$L.6\,Z=XIP?NMJ;D"XV>\XP:6_()<>VG%LM,^1&I9=I+S
M=<0;M3J?$>09,329'P(?(DY9J*&+SJ7DG+/V_P#OQ%9\@YQD;SC',[2VCBN2
M+8SQW845/C>"*1F*]5CDF$6P-M\;*H.I=7QN4MFFOY%M\J9`6>DC*P^-$'I4
M'OWW*Q-2XIJ1]CZ9VA>ZO0TYDBIXLBMME<8.WTW3JW(SBF(D,KEC'9V$2TD7
MCQ]/)U963*@541<KK)$,<"JJ>(''D_+1<+3F,L.%ER#\%%X`DDJ1"[-MN`9B
MBD1&2FXKU4-Z2RH25$1<+9_=LENT@LMU`Q`9MOSI5`?F!5:BE::95_FY_4A_
MP#]Y_EOU'_CK^1WW_P"7?F;;X/YY?YE_R+\KZ_F_]I^0?Y<__-?'[CX_N?K]
MQ]S_`+ESH7_3W[4?U;[?]:RWZ7^L_P")MDK]A^F^>G_B5I^H?Y6OC\U/AL_S
M.LG_`/2[]E+O;XJ[MT?U;-W;QUW[OZ>VNROK\E/3J1QSD_49HXTT<::.--'&
MFCC34?;VV>C;&^[K.=S=K^VKN*]KB(`\D'JA#QU+S,#!B=%M$7A!F'P1ME73
M110;SY$CKIE3(5R59$@%+Z;P[W`FPXCQF::27#J556'J>W0O5]BDC>@#,XBJ
MM6^EEW-7&NX7N`K5JR+M`/:E2U/P]1)_B=0I\08LR/A+9FP8NR[2I_'>0JE7
M[$QL52L[/[*4C5BKQ?BH(%.JV=LG!`\T7*"BK=8@@8AS%^O.I^!2VUQRVPDL
MY8Y[<S-M>,[D8>-Z%30&A^1`/S`/34%=QR);DNK+N6HJ"*]:=/GU!%145!&I
M%VAOK5R5MK+QMSM[>2H6`FKE)60M"Y#M)J[H%'S4C*,BH7L4%2@)%9(P?&@/
M]V4YNA#;_=KWLQ'`;-\;AWBN^6O51&"&2W(Z;YZ=R#VC[GX]-0UG:S94?Y)P
ML(:AEV[E]+4=4KT+_(D,GYG4N/#^&<:8%HT5CG%%4C:A4XDO:+!@0PK.W1B$
M(O)2KY8RCR4E7?Q@*SE<YU5#?4QAY^>_(>1YKE65DS6?G:XR4I]3&@'X!5%%
M51\%4`#X#6\6]O%:Q"&&NP$]R2>IKW-2?D*GH*#2H<A-7]'&FCC31QIHXTT<
M::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.
M--'&FCC31QIHXTUH;#%V.(O(<]EN.HU5990M->BJG8\@MH2/1N$Y6()PLZAJ
M_)SY$`DGD/&.G!U$&YU!23.83``"/)67.9F?#0\>FNIVP5O,\T=N78PI+(`)
M)%CKM5W"J&8"I`%3J\;B<P"V+L;<-N"UZ!B*5I\Z=*ZWSD5JSHXTT<::.--'
M&FCC31QIHXTT<::.--'&FCC31QIHXTT<::Y$V`T3U<V=N]#R/F+%L/8[OCQR
M88>QHB>,DY&'5`HN:I9'3(4E9ZK.ET4E3-%Q$"J(E$AB`)P-L_'N9<CXLY?!
MW+PFCTI0A6==A=:CHX6H5AVJ32NK-S`EV@CF+46E*$@@!MU!\@36H'>I^)UU
M9%Q49!QS&'AH]G%14:V191\;'-D6;%BT;D!-!LU:MR)HH()$*`%*4```YKDL
MLL\K33,SS.269B223W))ZDGXDZN(B1H(XU"QCL```/R`Z#7W\MZ^M'&FCC31
MQIHXTT<::P%IM-<I%;G;A;YJ.KE6K,4]F[!/2SE-G&1$1&H'=/I!\Z5$$T&S
M9NF8QC#^`!R_:VMS>W"6EG&\MU(P5$459F/0``=R3V&@!)H.I)TDL]LY@RMT
MG'.1)/(4.%/RX=NGC>89@YD4K>HZKTC:TTHA)B@NX74)7HATZ4*)0%--NIY=
M"40Y)6O'<]>SW-M:6=Q)<62[KA50[H5$B0[I!_*/+(D=3_.ZCXZ^WCDC\@=2
M#$:/_P`-&"'=\J,0OY]-;!4<[8?OLI6H:FY#K-CDKC592[59K%R";E2=J\%,
M)5^=EHX"_P!\C"3:Z;5X7Z*-5U"D4*4Q@#E+WC^=QJS/D+2XA2VF6*4NA41R
M.I9$>O9F4%E'\R@D5&JF*0+N*D+M1O\`Z9%W(?R=?4I^(ZZ^-QL-A%HEC)=U
MD^H-T<SV96FXH55ED")Y`M""+QPK"58XCXRKXJ,>N;P3[[!(PA^'+\/%>2W!
MOE@L+ISC(?+=TC;_`"T8(&^;_P!M:LHJWQ(U1HW24P.*3`$D?'H*G^P:N2V$
MPBN_R7%HY/IRDGAN>@JOE./),-C/:'/V=JP>UV+LK4#"M&N9II)H';`<`!4J
M@>(C]>OFXXQR.TMK.\NK&ZCM,C$\EJ[1L%N(XV*N\)I1U1E*L1V((.K]O97E
MU,MO;1223LNX*H))%":CYBBL?X'6(?[/X$C<EJ8@=Y.K1,AMIV*JS^O)NC+K
M1=HG8E"=A:W+.44U&49.RL.Z1<(-5U"+*)KI"!?[0G>6O"^4-ADY`+.88>2"
M29)"``\44JPO(H)JRB4E-P!!*24_PVI;%O<-X]L;D2A]E`:-XPS/3Y[`I+?*
MG7696V`PLVME)HKG)54;V[(]CR!4*+`+RB*4A:+5BOK^8=>ATE/'[N8J?U%V
M@4?D(!3?0?$>HX<?SALY<B+2X-A!%#+))L.Q([C_``'8_!9O^FQZ-\-?:V5V
MZ,ZQ.42,.QH:!&IM8_)344/XC6NS.U6O<%7JG:'V4ZN>'O;NPLJ8JQ=*2+FS
M+U%X^86D8=@R27>O$*ZYC'!7BI4_C0%(P&,`]`.<.&<M,ES#^G7GELO%YP8R
M##YPIA\E?I\@92@/5@P(Z:L2(\.X2@J4`+5^`)`!/YD@?QUOG\WL9CBV2S8G
M=()?%$14YV\R-Z0>%6@&M3K+)](3\VJ\(`@5G$M(QP=<>NT_A,`AV`AR,DP^
M5BROZ');S#,F81"':?(96(58PO<LS$``=R132)6G94A!9W("@=R3VI^=>GST
MFC';W7&0JEZNJ&5*ZG`8S&!"]K.CNF;NLA:EF#>L'DHURW2?IIV!>30(S."9
MBKG5`I1$W8!,0\'Y=/=VMBF.NONKU96@4I3RB`.92A/0^/QONZU&T_AJXMO.
M\2SHC-$Y8*0*U*?53_E^/RUEJWM#@2UD6&'R77CN6UOJ-"=QSM96/E65POYS
M$H\"\C'J*#UL]M@D$6`&(!7(`(D$>AZQFXERA8EF;'W0B>WFG4^,T,%MTN)1
M_P#CA/\`B-V7XZ^4BDDC$L:EHR&(('0A?J/Y#X_+6P73/.'L>0MJL%TR%6J]
M%4F<AZO9G,@_(D:-LUB*P-`5XR``*Z\W-C*-RM&R13JKF6*!2B(\Q<;@,WF+
MM+#%6L]Q>R0O*B(I9FBC5V>0`?R*(W);L-I^6JP0374GAME:27KT45/05/\`
M8.NM70VJU_<4A_D)')D`>L1EJ1HK]P!W`/V]T<-4G[>J&AS(!*C/N(U<CLC4
M$15,T-\P!\?[7,Z?AW*+>ZCLGL;@W4MJ+E5"[B8#WDZ5`52"K$GTN"AHPIKX
M"2%MFUM^W=2G\NW?N_+9ZJ_+KI0:[E;'UNHA\EUBSQ\Y2DF[]PK.1PJN$4_R
MM11&2041*G]RF\8KI&351$@*$4*)1#OD/?8V_P`9=FQR$,D-Z*51Q1ANH5Z?
MC44TD1X7*2@JZ]P>E-)/0=R-:LGQ#N>H^5Z[.0S*\UK&;F22^\0:)Y`MUFCZ
M;7ZC\KILB4T[(6B6;,2H!V<KA8I1Z[Y-9'A7+,->KCLSC[FTOGLVNU29=C-;
MHAD,RU/5-BE@1WITU<-O<!_'L;R;-]*==E"=_P#RT!-?D"=;K?=A,-XR^<EU
MOD-"NF]KBJ.>/4,NXDCVZ;JLC>(N`08-45G2\B\I\0[DB$(41^S;**?ND'D?
M88#.94.<9:3SB.W\[[$+;8!*L'E;Y1^9EBW'IY&"]SJR/4K,O54%6/\`=%0.
MORZL!_$:UM;;/71"ADR4IEBJA45+>KCXKXKLYW8WYNJJ@XI/Y21(TH%I;*H'
M!1E\/S$`HF$`*'?,U.'<KDO6QR8Z[-^EHMT8_&=PMV4.LW_;*LK!JT(/SU>C
MMYY?\-&;T;^@_EI7=^5.M=;+4-A<*WTM2&H9(K$ZI>9ZS56K-V3\IG<K9J9$
M.9ZVUY)J8I5TIFNQ#11P[;J%(HBF01$.N6KSBG)L>DTE]8744=O!%-*6C($<
M4[!(9'/P25R%1NS,0!KX\4GK&T_TZ;O^&M*5^5:C^T:^6W[(X.H<)'6"TY(K
M<;'3%ODZ##`+L7#V9N<(9\$S6XF.;$5?2,K$DBW*CE-),PHI('.;HI1'EJPX
MWG\I)/%CK.XFDMH!-*$0DQQ,4"R/_=4F2.A/?>M.^JQ0RSJ[PJ61%+,0*A5'
M<D_`#63IV><09`4I2-.OT!/N,B1EVF*<W8.A.XFV.-Y2%A+Z=NB8A5"*U&9L
M3)H_3.!3MW"Y2&`#=@%S)\8SF&>YCR5NT36CQ++4CTF=6>$CKZED1&=66H*T
M-:$:&&90Y9'`C;:U01M;J-K?(FAH/C0_+6VQE_I<S3AR%&V:'=4@L?(2QK21
MXD6%)&11G)9)^=\H)$2-&0LU?D.(@4OQCW^'(R>PO;:\..N(I$OU<*8R"'#&
ME%*]ZFHH/Q&JO#+%*8)%*S`TVD=:_*FD6K6XVLMM@K19H+,51=0-.HTID^P2
MBCM9HT9XWABD/(WTBCM!'[JIMR*D,+U+S1Z.4>_VB]S[\&YE'<16C8R\^ZN+
MM;6)/&2TER_T0(!U,C?RKW.KDEG=Q3_;21NLY<KM(-=PVU6GS&Y>GXC2YS5Q
MJ]<E:O"3T['1$I=9-U"5-F_<IME9^99QCN:7B8SY!*5U(EB8]PY!$H^9D4%#
M``@0>M=@M+FY262WC=T@B\DA4$A(]Z)O:G9=\B+4]-S*/CJRD;R;M@)VKN-/
M@*@5_*I&D3LNWNMM2A86P3F7*FVC+)*VV'K:J#L[Y:P.Z&NHA<CPK5BDX<R;
M&MF1,9VY2*9!(@>0GZ$.Y^/A?*Y[@VEO87,MRL<3LJK4JL]/%N_NE]P`4T:I
MH0-9+X^_B9UEAD5HP"U13:&I0G\#44_,:][CMGKM0VU/=V;*M99I7ZK.+S4@
M;KKR"LS2F969GEM008(.%B5YF,@@55T<I4R'5*41\AZXQW"^599Y5Q]A<2""
M[6UE.VBQW#%@L4C$@*Y*.`"?Y3\M6UM+I]P2-R5<*0!U#,:*M/F3T'XZ\+1M
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M\B&K="ZN\<G(W^X?NOXXCVR;Q_6B-&2"[@\HR:JE453`H^!!['Z<QH./YRY;
M9;VD[MX!/T4_X+?3+_R-\&^/PU9>&5/K4BL9?K_<`J6_(#K77U0V?,0SLWCN
MLLKS#)V7+,';[)CFNR"IXR<MT+0G4>SN#V'C'Z;=VY)`+2K<7!0+Y$35`_7C
MV(&P.92SN+][>46EI)'',U.D;2AC&&^6\(U#V^%:D:MJ&:/S*"8:@;@.E34@
M5[5-#0?&AUJ]YVPUWQO7JY:KCE2LQ,#;(>8L=???.N\+)5VO':)3T^BBR0<+
MEAH95^B5RX,4$DC*%`1['E_&<6Y)FKMK#$V-S<7RS+$8T0EA*Q(6.G]\E2`O
M>HU<@@FN2!;J7)('3KU(8C^T*Q'Y'7SS6W&O,%<W&/7628ES<F436)V0@(E"
M0EWT=#W-N1W59&0)'-'!6;6=:'!5L902@HF/D'TY<;B'*4QT>7?'W2XN5Y42
M4H1&[PG;,JL>A,3='`^D]#JU(##M,OI#5I7XT-#3\CTTEMF]A&NM;S'+83"6
ML4[9*J];L;S*5ZM2DK7::=6*-./UY.4;H&2=,ZK"@#Z?6;?,G!,#`Y>"DD!C
M!/6?MCR^\X_#R801QXNZC=X#)+&CS!6"*$C9@U9W)BM:@?<S`Q1;GZ&6M\->
MW%JUV%I&%!6O=R75`J_\1+54&FX`[:G7<'F3_:+^[Y_O!^Y_M?C^[_I_#GG^
MHG5W&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIKB'V%UUK:]
M8;A`V>_)8OQ,[DJVOG:\!%OYR1B\,L9MD\O+*%B(VLVQRZE)R/2!F0XLS)-R
M+&54$"%-S>_;B^7'\KBN4LEO\EX9A:1,^R/[QHV%N\O]6`M&DA#.HE0L!0'K
MJ5PSRI?J;=2]Y1A$!W\A'H/U+V/7O_`]M<DXYA\GTB8Q<6CV6BYQIS+<G.TQ
M@L[ES*XS>3%?F,*9=C<J4]P##'SNLMW]/S(A99%L\2!"(?QKD$6IP4;I$<;G
ME[W'W<5]^J6M[:9K_35E'>;%BE3R+>6+6TRB6\#B*2Q^UC*@M(LPJ8]C2/']
MM-.T=T##&LPMHU<JPZL)8B9)!UI(QHLBK5O)4N%;?31%:DV7HL(GBS)U,8;@
MRFR&[L_(A$-LIN8VJL+I<G:&X./\;SD=C'\WL(821L,$LQECP:#&SV^NL``J
M"\@8B4DV1NTR\D_)["1^)KB<*BHS6_K\-K%^D3W"O<#:+R&*031"YK;VUU,0
M66&,:OQO!_4:15^Q%J0`XB,S`/0,NYQ*FZ4;F$9D98B$4>(Q.MN<\=U>U6^I
MJ)9_88OQ;$8`HL%IFWIM0G+(_N&0$[$REIF\11T:!-HURZ+OT4(A5E7S+6$8
M59RY4230*/5>.9._M[*58,=/<99\C<29AKAT5([,QE1;N);E6DB`)E26^VP>
M<)%$&D/DU%;;*2RM?MFV7?W!IT@,==OI*!_74"H(8F,].N[23W"DU>7R)L7)
M068\=U#9MOL15K#L16H>!RC.U"1PW(5'5^$L^/L@33*@"#&8K]Z,C,T*1$AU
M'2B8-TE/M%IM%OLN1RE[#@\%'E,9?S\)/'I8<4\DMM%(MVMW?R"\@19I`RO'
MM@OH'847<=JN+69MZXU<7\-W;F*">:S\9"]54;]LQWH&<)N,7D!&\4K4AB$J
MX;C+^:L=(Y<K.-T=>I_%C_:ZSSS[*EFE9YK88"1?90BI;)5"O6,G%<C%I?*4
M-9BO(>JR99E-DI&J0C\GRIHIM7/E69DP+FPN,PF87+#!QJ8$$(@8B!DM9;>X
M\LA%NT7CGNH_MRWW`NH"49VEBU8&-FB+^=9A:,*1`%31#L*$/T1EW&Y^(D$M
M1N9E3DG,5/Q!)73";;(V6(*MJN-A][RXRDX2!R-+7^.S5/Y&@%J:OC>.B::9
MX_O%&D$EDY!%%5(CN.4>`V5<LONED]^XWDLG#@;U;#'F:Y_3,%N,KVBP?;QV
MTPE,QEG!$%PA!C.U@L@B\RQ2^)6S5EN1"3%$Y46MMN!*A2HCI5B#T5NZU'0[
M=R@T!UW6BL72KPNOCNN9"H>5<SL]2MGZ;=8&@?Q_CV>EH&0VFC9"RYGQ9:YC
M%LT5LI#7YFC'K5QU#)+@J^^=DJ\1:D*Y^N=7T%WE<HV3M+NTMSG,?)%Y5M98
MP!8;4M[F/[T(I,!67S+/*K!2DBQL_HB<O*7\BQQ(M74U9U,RCQT"C:"S*>A+
M`!:@5`8@:[*GJ[:6WJYV#@<F7F'>6*0U\V\/8+B[1FG,776MA0RW(-FDZI&4
M*O6.:7Q_#2*4?)O&]=2?2+B/6<$:**J@4^K8Z_L%][\)?</L7>TARF&^VMU=
M$:X:(6:C:TDSI$;N1#(JR3D0F4)(XV-3[A=OU2W=DFW@P55Z[R0J5H7(Z$_1
M4JNPK3:M`$`V3B[=<F^=Y#+\Y0,-S#K#>I%?B*W`2=^O]H95:.VF)*AD.4LD
M'C4$64I8+0Z<1$%#L6,LX1=,RO':B2;@R2&Q<`O8K&YQ1P]K?WUNMWFGDWBV
MA4S/C"C0QJ;LADC@$<TTKR0DAVBB1V12_P!6+*/&0%-QNFJ`$W@>.@]9DWE*
M=0&C50V_:SDD#5)*ILH;(N>&=;R8[NEB0VIU2O%0DL]HYQKM[D,T,99/^#<'
MVIQ)XM4B&.(I]--8U<L5:C%(=D*BJ3P5%2G<<R,5>7TN!Q=PUM%%;/QK)V[1
MVBV;B+&%3]S?J#>+/+>J]/N+:]GBE=@AB")1#<M7C%E&`LQ;PSJ2=NVG3<Z[
MF#%@:;EHJGIL([:5>R,K<YO<9<3R&+X[/C7=N%L='PU/2UY7IDM(H:R6>!F<
M>67([+'Z\3&W=_BIS/SD"_!LI#(3K:,;'<'<*"CS5,)<8Y;&^MVBO6XW)Q9$
MNY@EM]Q$1DA);S6\+W2AXVO!:P3()/-]NUP^Q5`;6-AVE/G$:RK`8&$YC.Y@
MO3U"HC]%=@=3N!7=5AN]*99%89+B:KE:VYK>QMCC9?9O&JU)P_)6K.*V7ZZJ
MUQ58XJ4;8CR7@[#5&R@SRW*`X_-F18R/L35*F-7K5RN#1RH=MF\5GP=Y/!C^
M.17MK/%A)EGNU6W\<LINXWC>_MKRYN++[,,$@/DD@C:Z:"4QJ\>V3)0SBT8V
M@F-,<VX/L"&LQ+["Y;^F*E5,8$AE4%5#EM.6ZC1U\C\0@.19DDM/R%RNDLW;
MK.5I&;KL'(SCAQ"56V3#RFT&4G+;`1YB(2#Q[&(O5G`"*QE3@*AO,N67&&N,
MFC8*%X;);6%2&`&^54`EE55FN%1)'JR(DI10:(%6BB*F1D*@O/(FQ2IE78VP
MCT@#<WH`Z(0>JT-!VTV3=:Q1PT]R4QN^1CFIROLKHTY9YFC1^<0M;5%+9W%[
MY[3*NE0Z0&4S9$=';_9L5H)JHD#Y=,R3TA`.LGZ[97.4GYKC3B;=8<H.+.D(
MG-B8BWV=P$E?SR/:>$DU875%V@^6.G0S=C),&MO"A+_I\BKUCH:B;U^M@NT5
M)(;K0'TGH#CJ;2\-/K73T\6Y<S;#50^]E9E&B]XC-HE<_)3C?13.,<YKD7_.
MW&4K=_E?-ESOR*.4S0X0B#LA'2;@4D#W+V_Y!;1YU>365G<9`\0CCE-JV.%J
M$_7;*1)V_39XH-H.R#;;`S><HTD)3RRZQ9FN3',MPL0?[8"L/B[>9#N?82N^
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MW,NVH?R*2&]6YA4`*Q"&A)"$#6P4>-LD9=<0VB`F:!9\XBPWD1E\4M)2\0D>
MG`6[*F+W]\>8YR-,8X6CW>1<2ST=7V`E=1S?\WCY&468%61;F$T!D+BR?CV:
MM/%=IQIKW#LMP5MFN%N(["X2*.2`7(I#<1/=3%XY)1$\5O')1Y!2L,DBXRZ2
MQBE:R,L=6\A`6C/M\BA#N#FI"U`1J#>Y`+\LR]*C6=ZUG?[GY:RS(.W%I]@<
MS4*[@M':^1R7%0%BN&ORL+3INP:ZX:I-EG2T%DQ.G8'LJTCVKF7>D^$STZ9U
M$]QX]=W5YCLLGM3:V=K&L6(61LB<25=TBNO+*J9>6>"/RRDF*.)Y72)5JX!-
M<V$WI\O@$@H(`OD\>PH$HC2>:M&=0'C5#L4,Z@E`IUV?3:OC]WZGV-60R7*0
M^/%,//FS#)BT%E>6E&L6%F=+QLC-05CKK#+SDYEP30DBO8TDD!!6,HF/0B.J
M-?Y2/WRDR`L89<J,F2;622U2,MXZ.OD$AM!_,T>V4Q$[0K`4`P(6CBR2LJ2R
MH).BSL%D8_)V8$*U>QVFG2@/329["1V=+-1MJW^67U+Q=3C^OW/-=<1#.ZVN
M^T`)][&5P$;U1THW`<3*Q]&AHABL9^1K)R,BJ+UL0(M0R95$Y/V[GXG8\XP%
MK@$O+_++RW'RK,\*02M`"U;>C7S1;VE935XT"M$U+G8Q!R[>25;E2D=PW^<1
MF#'LPW40U(1I&)D];E"`E:#>X3H+=1<;EJ#=D-@8B/PY.J7R@-L=N*G9[O>[
M4E:D+;6'5=DZ&\Q/3%<GI7-Z(R#7[>`CG+XD<5R=0X,SNA3TWV^DGM.7Q2\=
M1[N`6\OG2X2WBA,91@WW`GG-KX%8QL3<RK&9`@VEM@:&MV19D-RK&/<=PC+^
M385(D,>S:V\1;R/Y:`[P8]P.%`C""V*Q!9]6$\-9!47U*AZZCC!>=E:'#1^'
MT[G(/:GD/$5OAJ19Z;(LG-C658S480R#M-DBT7`ANTR'F+J?)2\+O++FT60A
M4<ADD:YVQS7!O#!&LL%U#-<0S`+&!)'(Q(,AD0==Q62<H;';<>55%PQ0D!BS
M%5#*P9E*L$]18!JGTD#OK88A3,M:RE)RV.&&#<IW69Q)!,<G54]BMF-*M37[
M>>MCFK36+I=Q3KA&3U"?.7+UG9DFQQ>?FC9!THFB=0&H0[_Z7NL.%RAO[.VC
MO*VQB2"YFEB(B6877]:W*S*H66UWA4$1EB1I:>35F_9Q;HERH:\$C>IBJN8M
MH_Q!5Y`:>,(#Z-I-"133?USAF3*IXFJV&;)1K1=;!A*\M*ADK"TKGW':N/+0
M[R;E)Q-2V3XBDXIROCRX:<L;)-R;>F-[[$(1J",#*&BA?IR3T[/UO'7;>:_O
M>0VUZF"AREH;V"Y7&S_<VP@B$21FZN[.\ARVQ`UZV.G,\C3I]S]L;=%GF2]D
MTL<EHDJ60GBVI'XF)15A\?A9&4^9W"^81`%=R[B2H![VB0S5"93V<B\6)X`O
M"5GN6)%\FW"YR]DK!,77)M@_%418&-LHR55<M[XU>T>-CIJ'.TFVI3)R:+!P
M9L1J+D_DC_Z7N,%BVY,U_;K#;W?B6**&1;B+[R=HJ2M<!X6^X>6)A)`RJD7E
M1Y&D""+OV4X^U`#K*(I*;@I4_P!9R#7?NIU8&J@@@4#`[AS#LK&U^.JD@^EY
MFSVE)#>C($F\@<.R&Q-4R"_D75*CF[N`A)?"6/[)D5B\C0#[AY]BFK&':C\8
MO3]#S=>,3Y2;)Q1XN*W@NSQRV2-[M<3+`%#L5DVY.XCLO7],1D)F5NJP5H-7
M+@RO<VNRB3+:#;N\95B%-/K)55;YGUCX*3KRR/7L6W6TZ9?Q/>K)A'(<AK_F
MJ%UJ&XM,X9.SQ6,U/L]ZRJT:Z1Z=[IL9?+4S@SQGC:6,X>-7<U:1>).R!!ED
MWC66P5_R''<=Y$K6/ZEC5SUA)DO$^/MK22V2RRHFMRUG*\,33([&"2TCEB1X
MMU1,8HI+\3WJ1RF=%<B:,RA3&(BH1_0Q6B#<*!2!424VD3;*Y+6V/RI3[%%3
M&)I#&.8\TR>BF`ZSE6GS=ERWCG$E6/%9/V1?8^R/29NP8AD&5AJ]LL\]:F4T
MR*=O/L&L"R449F*\2/S6<S<86\QTD&4BR5CQ@<OR,EM)&EK=71\D=D+FWD3[
MJVVRVT4=FR.F^"XDN)0'C\/JB+8V1"&Z`6SWU(7:TNRGJ!=BI*BBA"8PM3(W
M<;-(!?F\+`>P#),G8SY$R+;I?'6I[=Y!:P6;<^@U*J2T?!HI(R%G0P7B^T42
M2J,ZL;Y8].5FG*:464Q'((IB<0WZQGRUU[4XFUX]%;VMK"^6/EODX_*9X6N&
M)6$Y.[$R21M59?!;1R&7U1N_I&IX29(X"**TB3[(32$R.T8!)'T*CANH2A+`
M@DT`%*'70*%!P"?9R[KU7.<LE;+1<LA2[!N6J9*%#%CYM2["VR]4:XU0HRN-
MK\29@DYE:/?OG[5]%J*+F9A($`K8/-[W(9Z3@D8N["WCQ4%E"DY\EN3<H;F-
MK>68-)]Y%LE\*2K#MCE41^00O_5.'>O$T-P)ED3*#P+*>C!CM!1V*LAC_H[5
A"LLT1;:2$EVG3R'_`,=_YK_#G_B?\._]E_TG/&M0VO_9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
